Navigation Links
Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Date:2/27/2013

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol , M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... (PRWEB) , ... August 04, 2020 , ... Fifty six ... to respond more quickly and effectively to a healthcare crisis like COVID-19, according to ... is one of the most important issues for older voters this year,” says Mary ...
(Date:8/3/2020)... ... August 03, 2020 , ... Gottlieb, ... to welcome Michelle Kopronica as their new Vice President of Client Services. Kopronica ... management knowledge in leading and developing teams and delivering client-focused solutions. In this ...
(Date:8/3/2020)... ... ... Hide-a-Mask, a hat with a hidden face mask built-in, has tripled its ... launch. Hide-a-Mask is ideal for anyone who is forgetful or reluctant to wear a ... having a mask at your fingertips is a great way to navigate stores, airports ...
Breaking Medicine Technology:
(Date:8/7/2020)... ... August 07, 2020 , ... Belle Meade Family Dentistry, ... same-day dental implants with no referral necessary. This will make it easier for ... single, convenient location. This advantage is especially crucial during the COVID-19 pandemic because ...
(Date:8/5/2020)... , ... August 05, 2020 , ... ... Emotional Learning (SEL) program, has been named to the inaugural list of Best ... (AASL). , This recognition honors electronic resources that provide enhanced learning and ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... of Kathleen Cruger as Director of Clinical Services and Myron Falchuk, M.D. as ... , “ChronWell has achieved incredible growth as demand for remote care ...
(Date:8/5/2020)... ... August 04, 2020 , ... MemoryCare.com , a comprehensive ... Best Memory Care Facilities in Austin, Texas. The guide identifies 14 memory care ... According to the Alzheimer’s Association , 5.6 million people aged 65 and ...
(Date:8/3/2020)... WORTH, Texas (PRWEB) , ... August 03, 2020 ... ... company, today announced enrollment of the first patients with first-line advanced pancreatic cancer ... ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s ...
Breaking Medicine News(10 mins):